Mots-c Purity: 3691 Lab Tests Across 1278 Identified Manufacturers
113 studies on Mots-c curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 3,691 published third-party lab tests of Mots-c across 1,278 identified manufacturers. Among reports with a positive numeric purity result, the average is 99.46%. Within this published corpus, 2 positive purity results were below 90%, and 87 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
Mots-c average prices
As of 2026-09-03, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $8.88 | $8.00–$9.50 | $0.89 | 4 sources · 4 offers |
| 20 mg | $14.50 | $14.50–$14.50 | $0.72 | 1 source · 1 offer |
| 40 mg | $26.50 | $23.00–$32.50 | $0.66 | 5 sources · 5 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
We tested 3691 Mots-c batches across 1278 identified manufacturers
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 920 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Top 3 vendor evidence profiles for Mots-c
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 64 | 99.34% | 0 of 62 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → | |
| #2 | 49 | 99.49% | 0 of 44 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #3 | 27 | 99.42% | 0 of 27 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #101339 (99.4%) · #100727 (99.33%) · #100735 (99.68%) · #100903 (99.15%) · #101072 (99.68%) · #101092 (99.78%)
Mots-c studies and clinical research
-
Basal and post-exercise humanin, MOTS-c, SHMOOSE levels are preserved in cerebral palsy patients.
This research suggests that key mitochondrial signaling pathways, as indicated by stable MDP levels, are preserved in individuals with **cerebral palsy**, even in the presence of reduced muscle mass and cardiorespirat…
-
MOTS-c activates metabolism but paradoxically blunts reparative function in obese human mesenchymal stromal cells
This research significantly reframes the potential utility of **MOTS-c** in therapeutic applications involving **Mesenchymal Stromal Cells (MSCs)**, particularly in contexts like **obesity** where MSC function is comp…
-
MOTS-c suppresses systemic and cardiac NLRP3 inflammasome activation in diabetic rats
**MOTS-c could offer a novel therapeutic strategy for mitigating cardiovascular risk in diabetic patients** by directly targeting the `NLRP3` inflammasome, a critical pathway in diabetic cardiomyopathy. This preclinic…
-
Circulating MOTS-c Levels Significantly Reduced in Hashimoto's Thyroiditis, Linking Mitochondrial Dysfunction to Autoimmunity and Insulin Resistance
This study highlights **MOTS-c** as a promising biomarker for **Hashimoto's Thyroiditis (HT)**, reflecting the integrated autoimmune and metabolic dysregulation often seen in patients. **Monitoring MOTS-c levels could…
-
Review Maps Dysfunctional Mitochondrial Pathways and Precision Therapy Targets in Bone Aging
**This comprehensive review provides a critical framework for developing precision therapies against bone aging**, shifting focus from general anti-aging strategies to specific mitochondrial targets. By detailing the …
-
Mitochondrion-targeted therapies show promise for diabetic wound healing by restoring bioenergetics and redox balance
This review underscores that **targeting mitochondrial health is a critical, underexplored avenue for treating chronic diabetic wounds**, moving beyond symptomatic management to address a root cause of impaired healin…
-
Ramadan Dry Fasting vs. 16:8 Time-Restricted Feeding: Investigating Mitophagy and Mitochondrial DNA Dynamics
If this study demonstrates that Ramadan dry fasting elicits a stronger mitophagy response or distinct metabolic benefits compared to standard 16:8 fasting, it could significantly impact our understanding of optimal fa…
-
MOTS-c partially protects against skeletal muscle loss in C26 cancer cachexia
This study provides compelling preclinical evidence that **MOTS-c holds therapeutic potential for mitigating skeletal muscle loss in cancer cachexia**, a condition with limited effective treatments. The ability of MOT…
-
MOTS-c emerges as promising biomarker and therapeutic target for inflammatory lung diseases
This review significantly advances the understanding of **MOTS-c**'s potential in respiratory medicine, highlighting its dual role as a promising biomarker for disease severity and a therapeutic candidate. **Modulatin…
-
MOTS-c preserves mitochondrial bioenergetics and genome integrity, attenuating cardiac ischemia-reperfusion injury
This study highlights **MOTS-c** as a promising therapeutic candidate for **cardiac ischemia-reperfusion injury**, offering a novel approach to directly target mitochondrial dysfunction. For biohackers and clinicians,…
-
Physical Exercise Improves Mitochondrial Function to Counteract Cognitive Impairment
This review synthesizes evidence on how regular physical exercise mitigates age-related cognitive decline by enhancing mitochondrial biogenesis and efficiency.
-
Humanin and MOTS-c attenuate atrial fibrillation by suppressing fibrosis and mitochondrial dysfunction
This research highlights **Humanin** and **MOTS-c** as promising therapeutic candidates for **atrial fibrillation (AF)**, offering a novel approach beyond current rate and rhythm control strategies. By targeting funda…
-
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction
This research suggests that **Humanin and MOTS-c offer a novel therapeutic strategy for atrial fibrillation**, by directly targeting the underlying mechanisms of fibrosis and mitochondrial dysfunction, which are often…
-
MOTS-c peptide improves soft tissue transplant survival by reducing lysosomal membrane permeability and pyroptosis
This research identifies MOTS-c as a promising therapeutic strategy for improving outcomes in soft tissue transplantation and reconstructive surgery, particularly in scenarios prone to ischemic necrosis. By targeting …
-
MOTS-c attenuates hyperoxia-induced neonatal cardiac injury by inhibiting oxeiptosis via KEAP1-PGAM5 interaction
This research highlights MOTS-c as a potential therapeutic agent for preventing or treating hyperoxia-induced neonatal cardiac injury, a condition with limited specific treatments. Understanding that MOTS-c acts by in…
-
Urinary MOTS-c inversely correlates with oxidative stress, positively with arterial stiffness in PD patients
This pilot study highlights the complex and potentially dual role of MOTS-c in peritoneal dialysis (PD) patients, suggesting it could be a valuable biomarker for cardiovascular disease (CVD) risk. Monitoring MOTS-c le…
-
MOTS-c Levels Linked to Heart Attack Damage in Patients
This research highlights MOTS-c's potential as a novel and promising biomarker for assessing the severity of myocardial ischemia-reperfusion injury (IRI) in acute myocardial infarction (AMI) patients. Identifying pati…
-
Mitochondria-Targeted Nanotechnology Shows Promise for Heart Disease Treatment
-
MOTS-c Levels and Genetic Variation Linked to Polycystic Ovary Syndrome
These findings suggest that MOTS-c could serve as a novel biomarker for PCOS diagnosis or severity, and its genetic variants might identify individuals at higher risk. Understanding this metabolic link opens avenues f…
-
Mitochondrial Peptide MOTS-c Protects Sperm Production by Blocking Ferroptosis.
This research highlights MOTS-c as a promising therapeutic candidate for conditions involving impaired spermatogenesis. By targeting SLC7A11 and suppressing ferroptosis, MOTS-c offers a novel mechanism to protect germ…
-
TONE Trial Investigates High-Intensity Exercise for Chronic Kidney Disease Patients
This ongoing TONE Trial holds immense importance as it seeks to provide robust, high-quality evidence for the efficacy of structured, high-intensity combined exercise in a particularly vulnerable patient population: t…
-
Exercise Program's Impact on Breast Cancer Patients' Body Composition and Activity
Understanding the role of exercise in post-diagnosis breast cancer care is crucial for improving patient outcomes and quality of life. If this pilot study demonstrates positive changes in body composition and identifi…
-
Platelet Reactivity, Beta-Amyloid, and MOTS-c Predict Mortality in Diabetics with CAD
The ability to accurately predict cardiovascular mortality in Type 2 Diabetes Mellitus patients with Coronary Artery Disease is paramount for enhancing patient care and improving long-term outcomes. Positive findings …
-
MOTS-c Peptide Investigated for Insulin Sensitivity in Prediabetes and Obesity
MOTS-c is a novel mitochondrial-derived peptide with potential roles in metabolic regulation, including glucose homeostasis. If this Phase 2a study demonstrates significant improvements in insulin sensitivity and a fa…
-
Mitochondrial Peptides Humanin and SHLP6 Show Signs of Evolutionary Selection
Understanding the evolutionary history and selective pressures on humanin and SHLP6 provides crucial insights into their functional significance and potential roles in health and disease. The identification of sites u…
-
MOTS-c Peptide Levels Linked to Liver Fibrosis and Metabolic Health in MAFLD
This study provides compelling evidence that circulating MOTS-c levels are significantly associated with both metabolic health and the severity of liver fibrosis in patients with MAFLD. The consistent inverse relation…
-
MOTS-c Peptide Fights Hepatitis B by Remodeling Mitochondria
This research uncovers a novel antiviral mechanism for MOTS-c, demonstrating its potent ability to combat HBV infection by modulating mitochondrial dynamics. This unique approach could offer a significant advantage ov…
-
MOTS-c Levels Linked to Lower-Body Strength, Not Aerobic Fitness
These findings are significant because they identify MOTS-c as a potential biomarker for lower-body muscle strength, independent of aerobic fitness. This specificity could make MOTS-c a valuable tool for assessing mus…
-
MOTS-c Peptide Alleviates Inflammatory Pain Through Dual Central and Peripheral Actions
The findings suggest that MOTS-c holds significant promise as a novel therapeutic agent for managing inflammatory pain, leveraging its ability to act on both central and peripheral pain pathways. This dual mechanism o…
-
Aerobic Exercise Protects Diabetic Hearts by Boosting Antioxidant Peptide MOTS-c
This study highlights MOTS-c as a crucial mediator of the cardioprotective effects of aerobic exercise in diabetic myocardial injury, primarily through enhancing antioxidant defense. The findings suggest that targetin…
-
Mitochondrial Peptide MOTS-c Shows Promise for Heart Attack Recovery
This research highlights the significant therapeutic potential of MOTS-c as a novel intervention for myocardial infarction, offering a promising strategy beyond conventional treatments. By targeting mitochondrial func…
-
MOTS-c Peptide Shows Promise Against Diabetic Heart Damage in Type 1 Diabetes
This study provides compelling evidence that MOTS-c peptide could be a novel and effective therapeutic agent for diabetic cardiomyopathy. Its ability to improve cardiac function, reduce fibrosis, and mitigate oxidativ…
-
Mitochondrial Peptides Show Promise as Novel Antidiabetic Therapies
This research strongly positions mitochondrial-derived peptides as a novel and potent class of therapeutic agents for the management of Type 2 Diabetes. Their ability to simultaneously improve insulin sensitivity, red…
-
MOTS-c Microprotein Prevents Muscle Wasting and Fat Buildup from Immobility
This research highlights MOTS-c as a promising therapeutic agent for combating muscle wasting and associated fat infiltration caused by immobilization. The ability of MOTS-c to simultaneously preserve muscle mass and …
-
MOTS-c Peptide Interacts with Bcl-2 to Combat Fatty Liver Disease
This research highlights MOTS-c as a novel and potent regulator of NASH progression, acting through a direct interaction with Bcl-2 to mitigate hepatic steatosis, inflammation, and fibrosis. The findings underscore th…
-
Radiation Therapy Alters Mitochondrial Peptides Humanin and MOTS-c in Cancer Patients
This research is significant because it reveals that radiation therapy has a systemic impact on mitochondrial-derived peptides, which are crucial for cellular resilience and metabolism. The observed decrease in Humani…
-
Key Protein Worsens Sepsis-Induced Heart Damage by Disrupting Protective Pathway
This research identifies DNA-PKcs as a critical driver of myocardial microvascular injury during sepsis, highlighting it as a promising therapeutic target. The findings also underscore the protective role of MOTS-c, s…
-
Mitochondrial Peptide MOTS-c Directly Regulates Pancreatic Alpha and Beta Cell Functions
This study provides crucial in vitro evidence for the direct regulatory role of MOTS-c on pancreatic islet cells, suggesting its potential as a therapeutic agent for metabolic disorders. By simultaneously improving in…
-
Brain-Delivered MOTS-c Influences Reproductive Hormones Differently in Obese and Lean Rats
This study provides compelling and novel evidence that central MOTS-c administration can significantly modulate reproductive hormones, with distinct effects depending on the metabolic state of the individual. The abil…
-
Mitochondrial Peptide MOTS-c Protects Lungs from Acute Injury via Ferroptosis Inhibition
This research provides compelling evidence that MOTS-c offers significant protection against formyl peptide-induced acute lung injury by inhibiting FPR2-mediated ferroptosis and preserving endothelial barrier function…
-
Exercise Boosts Mitochondrial Peptide MOTS-c, Improves Metabolism in Diabetic Rats
This study underscores the critical role of mitochondrial MOTS-c (a mitochondrial-derived peptide involved in metabolic regulation) as a key mediator of exercise's beneficial effects on diabetes. The findings suggest …
-
Mitochondria-Derived Peptide Treats Painful Diabetic Neuropathy by Boosting Mitochondrial Biogenesis
This research provides compelling evidence that mitochondria-derived peptides represent a novel and promising therapeutic strategy for treating painful diabetic neuropathy. By directly targeting mitochondrial dysfunct…
-
Mitochondrial Dysfunction Linked to Cognitive Decline in Sleep Apnea Patients
The study unequivocally revealed a significant and consistent association between markers of mitochondrial dysfunction and poorer cognitive performance across several critical domains in adults with OSA. Specifically,…
-
MOTS-c Peptide Shows Promise for Relieving Cancer-Induced Bone Pain
This study identifies MOTS-c as a promising novel therapeutic agent for cancer-induced bone pain, addressing a significant unmet medical need in oncology. Its unique mechanism through AMPK-mediated mitochondrial bioge…
-
MOTS-c Peptide Reduces Lung Damage from Radiation Therapy
This groundbreaking research highlights MOTS-c as a highly promising novel therapeutic agent for the prevention and treatment of radiation pneumonitis. Its ability to simultaneously modulate inflammation, reduce oxida…
-
MOTS-c Peptide Shows Neuroprotective Promise in Traumatic Brain Injury
This study provides a robust mechanistic framework for understanding how MOTS-c protects the brain after traumatic injury, highlighting its role in enhancing mitochondrial function and reducing inflammation and oxidat…
-
Peptides Humanin and MOTS-c Protect Male Fertility from Chemo Damage
This research is significant as it identifies Humanin and MOTS-c as potential protective agents against chemotherapy-induced reproductive damage. Given the devastating impact of male infertility on cancer survivors, f…
-
Mitochondrial Peptide MOTS-c Predicts Mortality and Heart Risk in Dialysis Patients
This research highlights MOTS-c as a promising, novel biomarker that can significantly refine risk prediction for mortality and cardiovascular events in chronic hemodialysis patients. Identifying high-risk individuals…
-
Systematic Review Links Mitochondrial Peptides to Metabolic Health
This comprehensive systematic review and meta-analysis solidifies the critical role of Mitochondrial Derived Peptides (MDPs) in metabolic regulation and disease pathogenesis. The consistent and robust correlations obs…
-
SGLT2 Inhibitors Modulate Mitochondrial Peptides and Cellular Stress in Diabetic Heart Failure
This research significantly advances our understanding of the pleiotropic benefits of SGLT2 inhibitors in diabetic heart failure. By demonstrating their ability to enhance protective mitochondrial peptides and mitigat…
Research tools
Free, no account — handy when you're working with Mots-c.
